India, June 2 -- Candel Therapeutics Inc. (CADL), a clinical-stage biopharmaceutical company, on Tuesday announced encouraging results from the Phase 3 trial for Aglatimagene in treating high-risk localised prostate cancer. The data was published in The Lancet Oncology journal.
Aglatimagene besadenovec (CAN-2409) is a multimodal immunotherapy candidate comprising of an investigational, off-the-shelf, replication-defective adenovirus that delivers the Herpes simplex virus thymidine kinase (HSV-tk) gene directly to tumors, resulting in immunogenic death of the cancer cells.
The multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluated Aglatimagene in combination with valacyclovir and a standard-of-care radiotherapy i...